Nathan Fischman, MD
Urology · New Orleans, LANPI 1194894493
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,140 of the $1,394 with a category attached, or 81.8%. 7 manufacturers reported payments, led by Astellas Pharma US Inc at 48.0% of the total. That places this record below the midpoint for urology clinicians in LA, where the typical reported total is $2,723.
Across 40 payments — averaging $34.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$669
- Sumitomo Pharma America, Inc.$234
- Johnson & Johnson$142
- Exelixis Inc.$127
- Boston Scientific$97
- Janssen Scientific Affairs, LLC$96
- plus $28 from 1 others
Across 159 payments — averaging $8276.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$788K
- AbbVie$388K
- Urovant Sciences Inc$58K
- Imbrium Therapeutics L.p.$38K
- GSK$30K
- Sumitomo Pharma America, Inc.$9K
- plus $6K from 1 others
What the payments were for
- Food & beverage$1,14082%
- Education$25418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 28 | $669 |
| Sumitomo Pharma America, Inc. | 2 | $234 |
| Johnson & Johnson | 5 | $142 |
| Exelixis Inc. | 1 | $127 |
| Boston Scientific | 2 | $97 |
| Janssen Scientific Affairs, LLC | 1 | $96 |
| Pfizer | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,394 in reported general payments places this provider in the 30th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 194 | $129,734 |
| GemtesaVibegron | 101 | $73,587 |
| XareltoRivaroxaban | 11 | $6,278 |
| Tamsulosin Hcl | 593 | $5,822 |
| Trimethoprim | 143 | $5,743 |
| Methenamine Hippurate | 67 | $5,439 |
| Finasteride | 384 | $2,848 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 106 | $2,275 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,991 |
| Testosterone | 13 | $1,425 |
| Oxybutynin Chloride ErOxybutynin Chloride | 121 | $1,290 |
| Dutasteride | 31 | $1,150 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 50 | $697 |
| CefuroximeCefuroxime Axetil | 57 | $520 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 83 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $669 | $129,734194 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $234 | $73,587101 claims |
| Johnson & JohnsonXarelto | $142 | $6,27811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Jorge CasoNew Orleans$54K
- Lawrence JenkinsNew Orleans$33K
- Alexis ChesrowNew Orleans$17K
- Joanna TogamiNew Orleans$10K
- Neil BaumNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.